Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Kawasaki Disease

Cardiovascular

Kawasaki Disease (MCLS) Clinical Trials and Treatments

Also called mucocutaneous lymph node syndrome, MCLS, infantile polyarteritis

Kawasaki disease (KD) is an acute self-limited vasculitis of medium-sized arteries that predominantly affects infants and young children, particularly those under age 5 years. The exact etiology remains unknown but likely involves infectious triggers (viral superantigens, streptococcal peptides) in genetically susceptible individuals. Pathophysiology involves immune-mediated endothelial inflammation of coronary, cerebral, and mesenteric arteries.

In plain words, Kawasaki disease is a sudden illness of young children where blood vessels become swollen and irritated. Kids have a fever that lasts for days along with red eyes and a rash, and the heart's arteries can be affected.

Get an email when new Kawasaki Disease trials open or the FDA decides. Get alerts

Kawasaki Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 8 studies with no phase, like observational studies, and 2 phase 4 studies following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Immune globulin

Kawasaki Disease has 1 FDA-approved medicine, 13 open or active clinical trials (10 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Kawasaki Disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Kawasaki Disease

Clinically, KD presents with high fever persisting for 5 or more days accompanied by classic mucocutaneous findings including bilateral conjunctival injection without exudate, oral mucosa erythema with strawberry tongue, polymorphous exanthem on trunk and extremities, extremity edema and erythema with peeling, and often unilateral cervical lymphadenopathy. The diagnosis is clinical based on prolonged fever and at least 4 of 5 principal features.

Keep reading about Kawasaki Disease

The major complication is coronary artery abnormalities including aneurysm formation (occurring in 25% if untreated versus 5% with treatment), which can lead to myocardial infarction in childhood or adulthood. Risk factors for coronary involvement include delayed treatment, male gender, age <1 year, persistent or recurrent fever, and low hemoglobin. Early treatment dramatically reduces cardiac complications from 25% to <5%.

What are the symptoms of Kawasaki Disease?

These are common symptoms of Kawasaki Disease, and how strong they are varies from person to person.

  • Persistent fever lasting 5+ days
  • Bilateral conjunctival injection without exudate
  • Oral mucosa changes and strawberry tongue
  • Polymorphous rash on trunk and extremities
  • Extremity edema and erythema
  • Cervical lymphadenopathy (usually unilateral)

Who gets Kawasaki Disease?

Predominantly affects children under age 5 years, with peak incidence at 1-2 years of age. Rare in infants under 3 months and in children over 8 years but can occur at any pediatric age. More common in males with male-to-female ratio approximately 1.5-2.0:1.

Significantly higher incidence in Asian and Pacific Islander populations (200-300 per 100,000 children in Japan versus 10-20 per 100,000 in Western countries). African American and Hispanic populations have intermediate incidence rates. No clear seasonal or geographic clustering in most regions, though some autumn/winter predominance reported.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Kawasaki Disease?

There is currently 1 FDA-approved medication for Kawasaki Disease.

Immune globulin
immune globulin (human)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Kawasaki Disease

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Kawasaki Disease resources

Reputable organizations and medical references for learning more about Kawasaki Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Kawasaki Disease

Use this Kawasaki Disease clinical trial finder to see the 10 studies recruiting patients and 3 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 6 test a treatment and 7 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

13 active trials worldwide
Filter:
Sort:
RecruitingPatient registry covering many conditionsRecently updatedNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Sponsor: Sanford Health

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute...

Ages not specified1 location
Started Jul 2010Updated 3 weeks agoEst. Dec 2100 (~74y 2m)
Not yet recruitingTreatment trialPhase 2/3Recently updatedNCT07686770

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

Intervention: IVIG, Aspirin, Firsekibart

Sponsor: Children's Hospital of Fudan University

This study evaluates the efficacy and safety of the addition of Firsekibart to standard initial treatment (intravenous immunoglobulin [IVIG] plus aspirin) in children with Acute Kawasaki Disease (KD) .

Ages 29 Days to 17 Years2 locations
Expected to start Nov 2026Updated 3 weeks agoEst. Sep 2027 (~9 months)
RecruitingTreatment trialPhase 4Recently updatedNCT06978439

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Intervention: Rivaroxaban (Xarelto)

Sponsor: Children's Hospital of Fudan University

Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was proposed. This single-center, single-arm, pilot study a...

Ages 1 Month to 18 Years1 location
Started Jan 2024Updated 3 weeks agoEst. Dec 2027 (~1y 1m)
RecruitingPatient registry covering many conditionsRecently updatedNCT04278404

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Intervention: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:

Sponsor: Duke University · The Emmes Company, LLC

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is...

Ages 0 Years to 20 Years
Started Mar 2020Updated 2 months agoEst. Nov 2026 (11 days)
RecruitingTreatment trialPhase 4Updated a few months agoNCT05643651

Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

Intervention: Rivaroxaban Oral Tablet [Xarelto], Aspirin or Clopidogrel, Warfarin

Sponsor: Children's Hospital of Fudan University

Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibilit...

Ages 2 Years to 18 Years1 location
Started Jun 2025Updated 4 months agoEst. Jun 2027 (~6 months)
Find Kawasaki Disease trials near you, ranked by distance →
Active trial locations44 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+36 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Kawasaki Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Kawasaki Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Kawasaki Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Kawasaki Disease patients, caregivers and advocacy groups talk.

Companies developing Kawasaki Disease treatments

Drugmakers that list Kawasaki Disease in their rare disease portfolio, 1 in all.

Questions people ask about Kawasaki Disease